New BARD1 exosome liquid biopsy agreement with Griffith University

BARD1 Life Sciences (ASX:BD1) has announced a new project to develop its exosome liquid biopsy.

BARD1 said it has signed an agreement with Griffith University to provide consultancy and scientific services to support the development and evaluation of an exosome-based RNA test for the detection of ovarian and breast cancers.

It said the agreement will be delivered through the Mucosal Immunology Research Group (MIRG) at Griffith University that has significant expertise in RNA analysis and profiling infection and inflammatory/immune responses.

Plasma exosomes will be isolated using EXO-NET at BARD1’s US-based facility and then transferred to Griffith University for analysis using custom-built Nanostring expression assays.

The project aims to develop exosome-based RNA tests for earlier detection of breast and ovarian cancers by combining the BARD1’s EXO-NET exosome capture and biomarker technologies.

Chief scientific officer Dr Greg Rice said, “This project leverages the power of our EXO-NET technology to capture specific exosome populations and our BARD1 biomarker technology to enable the targeted profiling of exosomal RNAs thereby providing a more informative liquid biopsy for the presence of cancer.”

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.